BioWorld

Feb. 17, 2009

InterMune Prices Public Offering on Heels of Phase III IPF Data

A week after Phase III pirfenidone data in idiopathic pulmonary fibrosis sent its stock up 36 percent, InterMune Inc. decided to sell 3.5 million shares in a public offering. (BioWorld Today) Read More

Geron Seeking $50M Plus to Support More Trials

New Tissue Engineering Path: Micro-tissues Formed in '3-D'

Stimulus Bill Allots $10B for Biomedical Research

Holiday Notice

Corrections & Clarifications

Clinic Roundup

Earnings Roundup

Other News To Note

Restructuring Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...